Eglumetad (BioDeep_00000794668)

   


代谢物信息卡片


Eglumetad

化学式: C8H11NO4 (185.0688046)
中文名称: (1S,2S,5R,6S)-2-氨基二环[3.1.0]己烷-2,6-二羧酸
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CC(C2C1C2C(=O)O)(C(=O)O)N
InChI: InChI=1S/C8H11NO4/c9-8(7(12)13)2-1-3-4(5(3)8)6(10)11/h3-5H,1-2,9H2,(H,10,11)(H,12,13)/t3-,4-,5-,8-/m0/s1

描述信息

D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018690 - Excitatory Amino Acid Agonists
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
(rel)-Eglumegad ((rel)-LY354740) is a relative configuration of Eglumegad (HY-18941). Eglumegad is a highly potent and selective group II (mGlu2/3) receptor agonist with EC50s of 5 and 24 nM for transfected human mGlu2 and mGlu3 receptors, respectively[1].
Eglumegad (LY354740) is a highly potent and selective group II (mGlu2/3) receptor agonist with IC50s of 5 nM and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively.

同义名列表

7 个代谢物同义名

Eglumetad; LY 354740; (rel)-LY354740; (rel)-Eglumetad; (rel)-Eglumegad; LY354740; Eglumegad



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • K Gawel, M Jenda-Wojtanowska, E Gibula-Bruzda, E Kedzierska, J Filarowska, M Marszalek-Grabska, K K Wojtanowski, L Komsta, S Talarek, J H Kotlinska. The influence of AMN082, metabotropic glutamate receptor 7 (mGlu7) allosteric agonist on the acute and chronic antinociceptive effects of morphine in the tail-immersion test in mice: Comparison with mGlu5 and mGlu2/3 ligands. Physiology & behavior. 2018 03; 185(?):112-120. doi: 10.1016/j.physbeh.2017.12.035. [PMID: 29294304]
  • Fleur Gaudette, Adjia Hamadjida, Dominique Bédard, Stephen G Nuara, Francis Beaudry, Philippe Huot. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY-354,740 in rat and marmoset plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2017 Sep; 1061-1062(?):392-398. doi: 10.1016/j.jchromb.2017.07.007. [PMID: 28802219]
  • Manthena V S Varma, André H Eriksson, Geri Sawada, Youngeen A Pak, Everett J Perkins, Cheryl L Zimmerman. Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344). Drug metabolism and disposition: the biological fate of chemicals. 2009 Jan; 37(1):211-20. doi: 10.1124/dmd.108.022012. [PMID: 18838508]
  • Everett J Perkins, Trent Abraham. Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass bioactivation and dose linearity. Drug metabolism and disposition: the biological fate of chemicals. 2007 Oct; 35(10):1903-9. doi: 10.1124/dmd.107.016154. [PMID: 17646281]
  • Linda M Rorick-Kehn, Bryan G Johnson, Jennifer L Burkey, Rebecca A Wright, David O Calligaro, Gerard J Marek, Eric S Nisenbaum, John T Catlow, Ann E Kingston, Deborah D Giera, Marc F Herin, James A Monn, David L McKinzie, Darryle D Schoepp. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039). The Journal of pharmacology and experimental therapeutics. 2007 Apr; 321(1):308-17. doi: 10.1124/jpet.106.110809. [PMID: 17204749]
  • Linda M Rorick-Kehn, Everett J Perkins, Karen M Knitowski, John C Hart, Bryan G Johnson, Darryle D Schoepp, David L McKinzie. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. The Journal of pharmacology and experimental therapeutics. 2006 Feb; 316(2):905-13. doi: 10.1124/jpet.105.091926. [PMID: 16223873]
  • Will P J M Spooren, Philippe Schoeffter, Fabrizio Gasparini, Rainer Kuhn, Conrad Gentsch. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). European journal of pharmacology. 2002 Jan; 435(2-3):161-70. doi: 10.1016/s0014-2999(01)01562-x. [PMID: 11821022]
  • Jason T Johnson, Edward L Mattiuz, Sylvia H Chay, Jennifer L Herman, William J Wheeler, Kelem Kassahun, Steven P Swanson, Diane L Phillips. The disposition, metabolism, and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs. Drug metabolism and disposition: the biological fate of chemicals. 2002 Jan; 30(1):27-33. doi: 10.1124/dmd.30.1.27. [PMID: 11744608]
  • M P Johnson, G Kelly, M Chamberlain. Changes in rat serum corticosterone after treatment with metabotropic glutamate receptor agonists or antagonists. Journal of neuroendocrinology. 2001 Aug; 13(8):670-7. doi: 10.1046/j.1365-2826.2001.00678.x. [PMID: 11489083]
  • A Kłodzińska, M Bijak, E Chojnacka-Wójcik, B Kroczka, M Swiader, S J Czuczwar, A Pilc. Roles of group II metabotropic glutamate receptors in modulation of seizure activity. Naunyn-Schmiedeberg's archives of pharmacology. 2000 Mar; 361(3):283-8. doi: 10.1007/s002109900197. [PMID: 10731041]
  • P Malherbe, C Kratzeisen, K Lundstrom, J G Richards, R L Faull, V Mutel. Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain research. Molecular brain research. 1999 Apr; 67(2):201-10. doi: 10.1016/s0169-328x(99)00050-9. [PMID: 10216218]
  • A P Kozikowski, D Steensma, G L Araldi, W Tückmantel, S Wang, S Pshenichkin, E Surina, J T Wroblewski. Synthesis and biology of the conformationally restricted ACPD analogue, 2-aminobicyclo[2.1.1]hexane-2,5-dicarboxylic acid-I, a potent mGluR agonist. Journal of medicinal chemistry. 1998 May; 41(10):1641-50. doi: 10.1021/jm970719q. [PMID: 9572889]
  • B Fleischer. Localization of some glycolipid glycosylating enzymes in the Golgi apparatus of rat kidney. Journal of supramolecular structure. 1977; 7(1):79-89. doi: 10.1002/jss.400070108. [PMID: 24139]